Hovid Awarded TGA-GMP Certification, Enable Expansion into Global Markets
Hovid Berhad announced that the Company’s Chemor manufacturing facility has been awarded Therapeutic Goods Administration Good Manufacturing Practices (“TGA-GMP”) certification. Receipt of this certification is an essential requirement for the export of Hovid’s therapeutics goods into some developed countries such as Australia and New Zealand. This also verifies that Hovid’s manufacturing processes have been developed to produce quality products meeting international standards.
TGA-GMP is an international recognised certification by the Australia’s regulatory authority for therapeutic goods such as medicines, medical devices, and diagnostic tests, granted only to companies whose manufacturing procedures and facilities demonstrate a high degree of consistency, safety, and quality.
The certification enables Hovid to pursue international distribution opportunities especially in Australia and New Zealand, as well as in other global markets that accepts TGA-GMP certification fort market access. Hovid is one of the very few pharmaceutical companies in Malaysia to be granted the TGA-GMP.
“At Hovid, we are committed to providing patients worldwide with high quality products backed by our dedicated R&D facilities,” said David Ho, the Managing Director of Hovid Berhad. “By obtaining TGA-GMP certification, we can now embark upon our strategy and ambitious for expansion into more key international markets, aiming for rapid global growth and getting more Malaysian made products available globally.”
As the largest pharma exporter in Malaysia with a global sales and distribution network, Hovid will continue to aim for product excellence especially in quality. We will continuously innovate to improve our manufacturing lines and R&D based products that will penetrate market segments worldwide.
-End-